Mononucleótido de Nicotinamida

Sublingual NMN administration increases early circulating terminal catabolites 2PY and 4PY compared with oral administration in healthy adult men

Scientific reports · Wakabayashi J, Higashi S, Morifuji M · 17 de octubre de 2026

Resumen del estudio

curve (iAUC) was significantly higher for the terminal metabolites 2PY and 4PY following sublingual administration compared to the oral route. In contrast, no significant differences were found for the blood concentrations of NMN, NAM, or NAD⁺ between methods. Both administration routes were well-tolerated, with no adverse events reported. These findings provide the first direct evidence in humans that sublingual administration leads to a more rapid increase in the terminal metabolites (2PY and 4PY) over 0-60 min, although the metabolic origin of these increases could not be distinguished in the present study.

Detalles bibliográficos

Leer el estudio completo en PubMed →

Tienda

Productos con Mononucleótido de nicotinamida (NMN)

Productos de nuestra tienda formulados con este principio activo, basados en la evidencia que acabas de leer.

Compartir: